TYROSINE KINASE INHIBITOR
Calquence is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment, or adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Calquence is also referred to by its drug name, acalabrutinib.
Calquence is used as a targeted therapy for lymphoma. Calquence is a member of a class of drugs called tyrosine kinase inhibitors. Calquence is believed to work by blocking the growth of abnormal white blood cells, causing cell death.
How do I take it?
Prescribing information states that Calquence is given orally as a capsule approximately every 12 hours. It should be taken exactly as prescribed by the physician.
The FDA-approved label for Calquence lists common side effects that include anemia (low red blood cell count), thrombocytopenia (low blood platelet count), neutropenia (low white blood cell count), headache, diarrhea, fatigue, muscle pain, and bruising.
Serious side effects listed for Calquence include hemorrhage (bleeding), infections, very low blood cell counts, and irregular heartbeat.
For more details about this treatment, visit:
Calquence — AstraZeneca
Acalabrutinib — Chemocare